Neuronetics, Inc. (NASDAQ:STIM - Free Report) - Analysts at William Blair reduced their Q2 2024 earnings per share estimates for Neuronetics in a report released on Tuesday, May 7th. William Blair analyst M. Kaczor now expects that the company will earn ($0.27) per share for the quarter, down from their prior forecast of ($0.22). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Neuronetics' current full-year earnings is ($0.92) per share. William Blair also issued estimates for Neuronetics' Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.91) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.62) EPS.
Separately, Piper Sandler reiterated an "overweight" rating and set a $8.00 price target (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th.
Read Our Latest Analysis on Neuronetics
Neuronetics Trading Up 0.8 %
Neuronetics stock traded up $0.02 during trading hours on Friday, reaching $2.51. 197,466 shares of the company's stock were exchanged, compared to its average volume of 83,660. The company has a quick ratio of 4.33, a current ratio of 4.73 and a debt-to-equity ratio of 1.73. The firm's 50 day simple moving average is $3.93 and its 200 day simple moving average is $2.96. Neuronetics has a twelve month low of $1.03 and a twelve month high of $5.07. The firm has a market capitalization of $75.25 million, a PE ratio of -2.35 and a beta of 2.50.
Neuronetics (NASDAQ:STIM - Get Free Report) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07. The business had revenue of $20.31 million during the quarter, compared to the consensus estimate of $19.73 million. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. During the same period in the prior year, the business posted ($0.30) earnings per share.
Institutional Trading of Neuronetics
Large investors have recently made changes to their positions in the company. Cannell Capital LLC lifted its position in Neuronetics by 2.4% in the 3rd quarter. Cannell Capital LLC now owns 2,833,982 shares of the company's stock valued at $3,826,000 after acquiring an additional 65,240 shares in the last quarter. Kent Lake Capital LLC lifted its position in Neuronetics by 229.8% in the 3rd quarter. Kent Lake Capital LLC now owns 2,329,287 shares of the company's stock valued at $3,145,000 after acquiring an additional 1,622,938 shares in the last quarter. First Eagle Investment Management LLC lifted its position in Neuronetics by 33.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 776,009 shares of the company's stock valued at $1,048,000 after acquiring an additional 195,834 shares in the last quarter. Millrace Asset Group Inc. lifted its position in shares of Neuronetics by 205.1% during the 4th quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company's stock worth $2,104,000 after buying an additional 487,591 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC bought a new position in shares of Neuronetics during the 4th quarter worth approximately $545,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Neuronetics news, CEO Keith J. Sullivan sold 23,958 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $2.96, for a total transaction of $70,915.68. Following the completion of the sale, the chief executive officer now directly owns 1,434,171 shares in the company, valued at approximately $4,245,146.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP William Andrew Macan sold 15,621 shares of the firm's stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total value of $52,798.98. Following the completion of the sale, the executive vice president now directly owns 417,736 shares in the company, valued at approximately $1,411,947.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Keith J. Sullivan sold 23,958 shares of the firm's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $2.96, for a total value of $70,915.68. Following the completion of the sale, the chief executive officer now owns 1,434,171 shares of the company's stock, valued at $4,245,146.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,371 shares of company stock worth $399,574. Company insiders own 9.80% of the company's stock.
About Neuronetics
(
Get Free Report)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
See Also
Before you consider Neuronetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.
While Neuronetics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
